We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ULIHF market cap is 1.62B. The company's latest EPS is CNY 1.4867 and P/E is 0.60.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 8.39B | 8.77B | 9.7B | 11.33B | 13.74B |
| Operating Income | 1.09B | 1.32B | 1.46B | 2.09B | 3.28B |
| Net Income | 641.76M | 702.99M | 988.1M | 1.58B | 2.7B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 15.7B | 14.96B | 16.33B | 18.98B | 21.02B |
| Total Liabilities | 9.03B | 6.35B | 6.99B | 8.37B | 8.27B |
| Total Equity | 6.67B | 8.61B | 9.34B | 10.61B | 12.75B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | 1.8B | 1.57B | 1.54B | 2.03B | 2.44B |
| Investing | -433.25M | 166.76M | -587.22M | -594.92M | -1.56B |
| Financing | 317.73M | -1.91B | -620.93M | -24.17M | -1.36B |
| Market Cap | 1.62B |
| Price to Earnings Ratio | 0.60 |
| Price to Sales Ratio | 0.12 |
| Price to Cash Ratio | 0.38 |
| Price to Book Ratio | 0.13 |
| Dividend Yield | - |
| Shares Outstanding | 1.82B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 7.65% |
| 52 Week High | 0.8934 |
| 52 Week Low | 0.8299 |
| Spread (Intraday) | 0.29 (22.31%) |
| Company Name | United Laboratories International Holdings Ltd (PK) |
| Address |
cricket square grand cayman KY1-1111 |
| Website | https://www.tul.com.cn |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
